S.T.A.R.T. HIV treatment immediately after HIV diagnosis

The S.T.A.R.T. (“Strategic Timing of AntiRetroviral Treatment”) study is a randomized, controlled clinical trial designed to more clearly define the optimal time for HIV- infected individuals to begin antiretroviral therapy. Center leader Jens Lundgren represents one of the five big research groups involved in the study which includes 4.685 HIV-infected men and women from all over the world.

The study shows that the risk of AIDS, other serious illnesses or death was reduced by 53 percent among those in the early treatment group compared to those in the deferred treatment group.

Jens Lundgren, PERSIMUNECenter leader Jens Lundgren says, that the result is a milestone in HIV-research and he expects that changes in guidelines for HIV treatment will quickly happen. Not long after the press release from NIAID came out in the US the story of the major result landed on the front page of the NY Times.

Press release from the National Institute of Allergy and Infectious Diseases (NIAID)

More about S.T.A.R.T.

See feature in The New York Times



Newsletter